BIOGEN INC (BIIB:NASDAQ)
$200.07 0.11 (0.055%)
Analysed BIOGEN INC (BIIB:NASDAQ) News Sources
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
04-06-2026
yahoo.com
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
04-06-2026
yahoo.com
Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?
04-06-2026
yahoo.com
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
05-06-2026
yahoo.com
A Look At Biogen (BIIB) Valuation After New Breakthrough SMA Nod And Positive Lupus Phase 3 Data
05-06-2026
yahoo.com
Should Biogen’s (BIIB) New SMA Breakthrough and Lupus Data Prompt a Fresh Look From Investors?
05-06-2026
yahoo.com
EVERSANA Strengthens Commitment to Driving Market Access Growth with Addition of Industry Expert Jen Norton
09-06-2026
yahoo.com
How Is Biogen’s Stock Performance Compared to Other Biotech Stocks?
10-06-2026
barchart.com
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky
10-06-2026
yahoo.com
What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names
11-06-2026
yahoo.com
What is the current price of BIOGEN INC (BIIB:NASDAQ)?
The current price of BIOGEN INC (BIIB:NASDAQ) is $200.07.
BIOGEN INC (BIIB:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIOGEN INC (BIIB:NASDAQ) since the previous trading day is $0.11.
BIOGEN INC (BIIB:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIOGEN INC (BIIB:NASDAQ) since the previous trading day is 0.055%.
What is the most recent average sentiment score for BIOGEN INC (BIIB:NASDAQ)?
The most recent average sentiment score for BIOGEN INC (BIIB:NASDAQ) is 67 out of 100.
What is the most recent average sentiment for BIOGEN INC (BIIB:NASDAQ)?
The most recent sentiment for BIOGEN INC (BIIB:NASDAQ) is .
SEC-8K** Filing Available For BIOGEN INC (BIIB:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.